Funding for this research was provided by:
Received: 26 May 2021
Accepted: 19 September 2021
First Online: 9 October 2021
: Participants were recruited through an advocacy group or clinical sites in the US and Germany with study materials approved by a centralized independent review board (IRB), Copernicus Group IRB, and, for clinical-site interviews, through local ethics committees associated with Stanford University in the US and Mannheim University in Germany.
: Not applicable.
: FT, REL, BP, IM, and ALS are, or were at the time of the research, employees of Adelphi Values, which conducted research on behalf of Blueprint Medicines. CA received research funding and consultancy fees from Blueprint Medicines. TG, ALB, and BM are employees of Blueprint Medicines and own stock in the company. FS is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Moxie, Novartis, and Uriach.